Ionis Pharmaceuticals (IONS) said Monday the US Food and Drug Administration has accepted for review a new drug application for donidalorsen for prophylaxis to prevent attacks of hereditary angioedema in adults and patients 12 years of age and older.
The regulator has set an action date of Aug. 21, 2025, under the Prescription Drug User Fee Act, the company said.
Hereditary angioedema is a rare genetic disease that causes recurrent attacks of severe swelling in several parts of the body, Ionis said.
Price: 38.72, Change: -0.04, Percent Change: -0.10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.